Eurizon Capital SGR SpA’s Vaxcyte PCVX Stock Holding History

Eurizon Capital SGR SpA’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.9K	Hold	1,383	–	–	﹤0.01%	946
2026 Q1	$76.4K	Hold	1,383	–	–	﹤0.01%	951
2025 Q4	$62.7K	Buy	+1,383	New	+$61.9K	﹤0.01%	882

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Eurizon Capital SGR SpA's PCVX Position: Q2 2026 in Review

Eurizon Capital SGR SpA held its Vaxcyte (PCVX) position steady in Q2 2026 at 1,383 shares worth $79.9K. The position accounts for ﹤0.01% of the portfolio, ranked #946.

Eurizon Capital SGR SpA first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Eurizon Capital SGR SpA held 1,383 shares of Vaxcyte worth $79.9K as of Q2 2026.
Eurizon Capital SGR SpA left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #946 holding.
Eurizon Capital SGR SpA first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.